Twist Bioscience
TWST
Market cap $2.61B

44.58 USD

-0.77

1.70%

Updated Oct 22, 10:46 AM EDT

1 day

-1.70%

5 days

-4.56%

1 month

-1.57%

3 months

-20.70%

6 months

51.38%

Year to date

28.70%

1 year

180.03%

5 years

88.02%

About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.

Employees: 919

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]

80% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 35

68% more call options, than puts

Call options by funds: $12.2M | Put options by funds: $7.25M

40% more capital invested

Capital invested by funds: $2.33B [Q1] → $3.25B (+$926M) [Q2]

16% more repeat investments, than reductions

Existing positions increased: 89 | Existing positions reduced: 77

12% more funds holding

Funds holding: 233 [Q1] → 261 (+28) [Q2]

4.12% less ownership

Funds ownership: 117.43% [Q1] → 113.31% (-4.12%) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$35

21%

downside

Avg. target

$48

8%

upside

High target

$56

26%

upside

5 analyst ratings

3 positive

60%

1 neutral

20%

1 negative

20%

Leerink Partners	8%upside $48	Market Perform Maintained	17 Oct 2024
Evercore ISI Group Vijay Kumar 80% 1-year accuracy 24 / 30 met price target	26%upside $56	Outperform Maintained	1 Oct 2024
Barclays Luke Sergott 48% 1-year accuracy 23 / 48 met price target	23%upside $55	Overweight Maintained	5 Aug 2024
JP Morgan Tycho Peterson 33% 1-year accuracy 2 / 6 met price target	21%downside $35	Underweight Maintained	5 Aug 2024
Baird Catherine Ramsey 100% 1-year accuracy 7 / 7 met price target	3%upside $46	Outperform Maintained	5 Aug 2024

See Analyst Rankings

Financial journalist opinion

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has entered into a royalty purchase agreement with XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator. Under the terms of the agreement, XOMA Royalty will provide Twist Bioscience an upfront payment of $15 million in cash in exchange for the right t.

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Mike Fero, Ph.D., as chief information officer. Dr. Fero brings more than 30 years of experience leading startups, developing commercial software, researching biology and physics and working in fast-paced deep-tech businesses. “Mike's extensive backgroun.

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the U.S. Green Building Council (USGBC) awarded the company's Wilsonville, OR facility LEED certification, meeting sustainability standards for its building, operations and maintenance. “We founded Twist to improve health and sustainability, and every day we work towa.

Twist Bioscience Achieves LEED Certification for Sustainable Operations and Maintenance

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today released its 2024 corporate responsibility report detailing Twist's approach to sustainability, social responsibility and ethics. The report highlights Twist's ongoing commitment to advancing sustainable initiatives to best serve customers, communities and the planet. “At Twist, we'.

Twist Bioscience Releases 2024 Corporate Responsibility Report and Quantifies Carbon Footprint of Oligo Manufacturing Process for NGS Target Enrichment Panels

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the Baird Global Healthcare Conference 2024 in New York City on Tuesday, September 10 at 2:35 p.m. Eastern Time. The presentation will be webcast live and can be accessed by visiting the “I.

Twist Bioscience to Present at Baird Global Healthcare Conference 2024

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its DNA synthesis offering with the launch of Gene Fragments with increased lengths ranging from 1.8kb to 5.0kb. “Leveraging our Express Genes workflow, industry-leading error rate and rapid turnaround times, we continue to push the boundaries of what is p.

Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Markets tanked on Monday because the Japanese central bank raised its interest rate to 0.25%. Interest rates were originally at a benchmark between 0 and 0.1, meaning a minor 15- to 25-basis-point increase had significant consequences for investors who were making margin calls with Yen.

3 Healthcare AI Stocks Positioned for Potential Breakthroughs

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 94,200 restricted stock units (“RSUs”) to 30 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment ind.

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

The 3 Best Med Tech Stocks to Buy Now

According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.

The 3 Best Med Tech Stocks to Buy Now

Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis

SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and bitBiome Inc., a biotechnology company unlocking the potential of our planet's microbes to power the future of the bioeconomy, today announced the launch of a joint Transaminase Enzyme Screening Kit, which is a curated collection of forty-eight highly diverse transaminase enzy.

Twist Bioscience and bitBiome Announce Strategic Collaboration and First Offering to Deliver One-of-a-Kind Enzymes for Biocatalysis

See News Rankings

Charts implemented using Lightweight Charts™